Tumor antagonizing genes and ovarian cancer: the role of the human RNASET2 gene.
Francesco Acquati(University of Insubria), Roberto Taramelli(University of Insubria), Paola Bonetti(Center for Pediatric Endocrinology Zurich), Annalisa Grimaldi(University of Insubria), Francesca Sanvito(Vita-Salute San Raffaele University), Claudio Doglioni(Vita-Salute San Raffaele University), Raffaella Cinquetti(University of Insubria), Cristina Riva(Ospedale di Circolo e Fondazione Macchi), Marta Lualdi(University of Insubria), Paolo Ghia(Vita-Salute San Raffaele University), Carlo Capella(University of Insubria), Douglas M. Noonan(University of Insubria), S Bertilaccio(Lymphoma Research Foundation), A. Sica, Laura Monti(Institute of Molecular Science and Technologies)
IrInSubria (University of Insubria)
January 1, 2011
Cited by 0
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
|Gastroenterology|1997|1.4k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890